L.E.A.P.S.(TM) Scientific Backgrounder

L.E.A.P.S.(TM)* (Ligand Epitope Antigen Presentation System) is a CEL-SCI patented platform technology designed to stimulate antigen-specific immune responses in T-cells using synthetic peptides. L.E.A.P.S.(TM) constructs physically link the antigenic peptide with a T-cell binding ligand and are delivered directly to the recipient immune system by injection or mucosal absorption, potentially enhancing T-cell responses to a particular antigen.

The antigenic L.E.A.P.S. constructs can be designed using the L.E.A.P.S. technology to preferentially elicit either a primarily (cellular) Th1 response or a humoral (antibody mediated) Th2 type response, following administration to an animal. This technology is being developed and currently being tested in animal models for the treatments and/or vaccines against a number of target diseases, including herpes simplex and malaria, as well as autoimmune myocarditis.

CEL-SCI has received funding from the US Government to continue preclinical studies aimed at determining the usefulness of several L.E.A.P.S.(TM) hybrid antigen/T-cell binding peptide constructs to treat and/or prevent Herpes Simplex Virus infection in these animal models.

 

No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.

* L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review.